Literature DB >> 7273481

Experimental nephrosis: interassociation of proteinuria with impaired lymphocyte blastogenesis.

M A Minchin, G D Bower, K J Turner.   

Abstract

The drug puromycin aminonucleoside (PA), used to induce an experimental nephrosis in rats, inhibited the blastogenic response of normal rat spleen cells when cultured in vitro with autologous or heterologous serum. Only at final PA concentrations of less than 5 microgram/ml did PHA induce normal blastogenesis. When PA was unilaterally perfused through the rat kidney a nephrosis developed, characterized by massive proteinuria. Microscopically, the foot process fusion and mesangial cell increase were similar to that seen in human steroid-responsive nephrotic syndrome. Once proteinuria had developed, there was marked suppression of the lymphocyte blastogenic response of the nephrotic rat spleen cells when cultured in autologous sera. Neither proteinuria nor inhibited blastogenesis was found in animals perfused with a buffered salt solution. Animals which were perfused with PA, nephrectomized 2 days after perfusion, and did not show proteinuria, had suppressed lymphocyte blastogenesis after stimulation with PHA. However, the degree of stimulation by the spleen cells of these animals was similar to that from control perfused and nephrectomized animals. Therefore, the aberration in lymphocyte response was consistent with the development of the nephrosis and proteinuria.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7273481      PMCID: PMC1537297     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  8 in total

1.  The effect of a single intravenous injection of aminonucleoside of puromycin on the rat kidney: a light- and electron-microscope study.

Authors:  R LANNIGAN; R KARK; V E POLLAK
Journal:  J Pathol Bacteriol       Date:  1962-04

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

4.  Inhibition of aminonucleoside nephrosis in rats. IV. Prevention by N6-methyladenosine.

Authors:  R F Derr; D K Loechler; C S Alexander; H T Nagasawa
Journal:  J Lab Clin Med       Date:  1968-09

5.  Unilateral renal disease in the rat. I. Clinical, morphologic, and glomerular mesangial functional features of the experimental model produced by renal perfusion with aminonucleoside.

Authors:  J R Hoyer; S M Mauer; A F Michael
Journal:  J Lab Clin Med       Date:  1975-05

6.  An ultrastructural study of the mechanisms of proteinuria in aminonucleoside nephrosis.

Authors:  G B Ryan; M J Karnovsky
Journal:  Kidney Int       Date:  1975-10       Impact factor: 10.612

7.  Transfer of aminonucleoside nephrosis by renal transplantation.

Authors:  J R Hoyer; J Ratte; A H Potter; A F Michael
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

8.  Relationship between RNA synthesis, cell division, and morphology of mammalian cells. I. Puromycin aminonucleoside as an inhibitor of RNA synthesis and division in HeLa cells.

Authors:  G P Studzinski; K A Ellem
Journal:  J Cell Biol       Date:  1966-06       Impact factor: 10.539

  8 in total
  3 in total

1.  Effect of indomethacin on lymphocyte response to mitogens in puromycin aminonucleoside nephrosis in the rat.

Authors:  E H Garin; T M Barratt
Journal:  Clin Exp Immunol       Date:  1982-09       Impact factor: 4.330

2.  Plasma inhibition of lymphocyte proliferation in nephrotic syndrome: correlation with hyperlipidemia.

Authors:  C Lenarsky; S C Jordan; S Ladisch
Journal:  J Clin Immunol       Date:  1982-10       Impact factor: 8.317

3.  Impaired primary antibody response in experimental nephrotic syndrome.

Authors:  E H Garin; P J Sausville; G A Richard
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.